EUROPE DNA VACCINE MARKET FORECAST 2018-2026
Europe DNA Vaccine Market by Type (Animal DNA Vaccine, Human DNA Vaccine) by Application (Human Disease, Veterinary Disease) by Technology (Plasmid DNA Vaccines, Plasmid DNA Delivery) by Geography
Europe DNA vaccine market was calculated to be at $XX million in the year 2017. The market is projected to expand further at a CAGR of 41.34%, generating around $XX million by the end of the forecast period of 2018-2026.
To learn more about this report, request a free sample copy
The countries analyzed for this market include the United Kingdom, France, Spain, Germany, along with the rest of Europe. The market is chiefly segmented on the basis of type, application, and technology. The various developments in the field of nanotechnology and biotechnology are significantly responsible for increasing the demand of the market. Also, the fact that these vaccines are comparatively stable than the traditional vaccines makes it easy for their storage and transport. The market finds its application in human as well as veterinary diseases. Because of the rising global travel of people, animals, and commercial goods, the risk of disease transmission and spread has increased considerably. This, in turn, is largely increasing the demand for the market.
Some of the well-known DNA vaccine market companies include Sanofi, Zoetis Inc, Eurogentec S.A, Astellas Pharma Inc, Eli Lilly And Company, Glaxosmithkline Inc, Merck & Co, Xenetic Biosciences Inc, Inovio Pharmaceuticals Inc, Novartis Ag, Madison Vaccines Incorporated (MVI), and Vical Incorporated.
To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.
- RESEARCH SCOPE
- STUDY GOALS
- SCOPE OF THE MARKET STUDY
- WHO WILL FIND THIS REPORT USEFUL?
- STUDY AND FORECASTING YEARS
- RESEARCH METHODOLOGY
- SOURCES OF DATA
- SECONDARY DATA
- PRIMARY DATA
- TOP DOWN APPROACH
- BOTTOM-UP APPROACH
- DATA TRIANGULATION
- SOURCES OF DATA
- EXECUTIVE SUMMARY
- MARKET SUMMARY
- KEY FINDINGS
- MARKET DETERMINANTS
- DRIVERS
- DNA VACCINES SHOW GREAT PROMISE IN CHECKING THE RISING PREVALENCE OF DISEASES
- THIRD GENERATION VACCINATION IS SEEING A SURGE IN INVESTMENT
- INCREASING ADOPTION OF DNA VACCINES FOR ANIMAL HEALTHCARE
- RESTRAINTS
- LENGTHY REGULATORY PROCESS
- POOR PATENT PROTECTION IN SOME COUNTRIES
- OPPORTUNITIES
- TRANSFORMING HEALTHCARE LANDSCAPE
- NEW DEVELOPMENTS IN BIOTECHNOLOGIES AND NANOTECHNOLOGIES
- STABLE VACCINES MAKE IT ATTRACTIVE TO STORE AND TRANSPORT
- CHALLENGES
- VACCINES FOR HUMAN USAGE STILL UNDER CLINIC TRAIL PHASE
- DRIVERS
- MARKET SEGMENTATION
- MARKET BY TYPE 2018-2026
- ANIMAL DNA VACCINE
- HUMAN DNA VACCINE
- MARKET BY APPLICATION 2018-2026
- HUMAN DISEASE
- VETERINARY DISEASE
- MARKET BY TECHNOLOGY 2018-2026
- PLASMID DNA VACCINES
- PLASMID DNA DELIVERY
- MARKET BY TYPE 2018-2026
- KEY ANALYTICS
- PORTER’S FIVE FORCE MODEL
- THREAT OF NEW ENTRANTS
- THREATS OF SUBSTITUTE PRODUCT
- BARGAINING POWER OF BUYER
- BARGAINING POWER OF SUPPLIER
- INTENSITY OF COMPETITIVE RIVALRY
- KEY BUYING CRITERIA
- EFFICACY
- COST-EFFECTIVENESS
- STABILITY
- KEY MARKET PLAYERS
- VICAL INCORPORATED
- SANOFI
- MERCK AND CORP
- GSK
- OPPORTUNITY MATRIX
- VALUE CHAIN ANALYSIS
- R&D
- MANUFACTURING
- RAW MATERIALS
- MARKETING, DISTRIBUTION & END USER
- LEGAL, POLICY AND REGULATORY FRAMEWORK
- PORTER’S FIVE FORCE MODEL
- GEOGRAPHICAL ANALYSIS
- EUROPE
- UNITED KINGDOM
- FRANCE
- GERMANY
- SPAIN
- REST OF EUROPE
- EUROPE
- COMPETITIVE LANDSCAPE
- STRATEGIC INITIATIVES
- ACQUISITION
- PARTNERSHIP
- COLLABORATION
- INNOVATION
- DISINVESTMENT
- EXPANSION
- STRATEGIC INITIATIVES
- COMPANY PROFILE
- MARKET SHARE
- ASTELLAS PHARMA INC.
- OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVE
- DENDREON CORPORATION (ACQUIRED BY SANPOWER GROUP)
- OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVE
- ELI LILLY AND COMPANY
- OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVE
- EUROGENTEC S.A
- OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVE
- GLAXOSMITHKLINE INC.
- OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- INOVIO PHARMACEUTICALS, INC.
- OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVE
- MADISON VACCINES INCORPORATED (MVI)
- OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- MERIAL LIMITED (ACQUIRED BY BOEHRINGER INGELHEIM)
- OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVE
- MERCK & CO.
- OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVE
- NOVARTIS AG
- OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVE
- SANOFI
- OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVE
- VGXI
- OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- VICAL INCORPORATED
- OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVE
- XENETIC BIOSCIENCES INC.
- OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATES
- ZOETIS INC
- OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATES
LIST OF TABLES
TABLE 1 EUROPE DNA VACCINE MARKET 2018-2026 ($ MILLION)
TABLE 2 INTERVENTIONS AND PHASE OF CERTAIN DISEASE/CONDITIONS
TABLE 3 APPROACHES BEING TESTED TO ENHANCE THE LOW IMMUNOGENICITY
TABLE 4 CLINICAL TRIALS OF THE HUMANS INVOLVING DNA VACCINES
TABLE 5 TEMPERATURE REQUIREMENTS IN PRESERVATION FOR VARIOUS VACCINES
TABLE 6 EUROPE DNA VACCINE MARKET BY TYPE 2018-2026 ($ MILLION)
TABLE 7 EUROPE DNA VACCINE MARKET IN ANIMAL DNA VACCINE 2018-2026($MILLION)
TABLE 8 EUROPE DNA VACCINE MARKET IN HUMAN DNA VACCINE 2018-2026
TABLE 9 EUROPE DNA VACCINE MARKET BY APPLICATION 2018-2026 ($ MILLION)
TABLE 10 EUROPE DNA VACCINE MARKET IN HUMAN DISEASES APPLICATION 2018-2026 ($MILLION)
TABLE 11 EUROPE DNA VACCINE MARKET IN VETERINARY APPLICATION 2018-2026
TABLE 12 EUROPE DNA VACCINE MARKET BY TECHNOLOGY 2018-2026 ($ MILLION)
TABLE 13 EUROPE DNA VACCINE MARKET IN PLASMID DNA VACCINES TECHNOLOGY 2018-2026
TABLE 14 EUROPE DNA VACCINE MARKET IN PLASMID DNA DELIVERY TECHNOLOGY 2018-2026
TABLE 15 REGULATONS TO BE FOLLOWED BEFORE COMMERCIALIZATION
LIST OF FIGURES
FIGURE 1 EUROPE DNA VACCINE MARKET 2018-2026 ($ MILLION)
FIGURE 2 EUROPE DNA VACCINE MARKET IN VETERINARY DISEASES 2018-2026 ($ MILLION)
FIGURE 3 SHARE OF TRIALS BY VACCINE TARGET IN 2016
FIGURE 4 SEGMENT OF CLINICAL TRIALS OF DNA VACCINE BY CANCER MARKS IN 2016
FIGURE 5 CLINICAL TRIALS OF GENE THERAPHY
FIGURE 6 EUROPE DNA VACCINE MARKET SHARE BY TYPE 2017 & 2026 (%)
FIGURE 7 EUROPE DNA VACCINES MARKET IN ANIMAL DNA VACCINES 2018-2026 ($ MILLION)
FIGURE 8 EUROPE DNA VACCINE MARKET IN HUMAN DNA VACCINES 2018-2026($ MILLION)
FIGURE 9 EUROPE DNA VACCINE MARKET SHARE BY APPLICATION 2017 & 2026 (%)
FIGURE 10 EUROPE DNA VACCINES MARKET IN HUMAN DISEASES 2018-2026 ($ MILLION)
FIGURE 11 EUROPE DNA VACCINES MARKET IN VTERINARY APPLICATION 2018-2026 ($ MILLION)
FIGURE 12 EUROPE DNA VACCINES MARKET IN PLASMID DNA VACCINES TECHNOLOGY 2018-2026 ($ MILLION)
FIGURE 13 EUROPE DNA VACCINES MARKET IN PLASMID DNA DELIVERY TECHNOLOGY 2018-2026 ($ MILLION)
FIGURE 14 VALUE CHAIN ANALYSES FOR DNA VACCINE INDUSTRY
FIGURE 15 UNITED KINGDOM DNA VACCINE MARKET 2018-2026 ($ MILLION)
FIGURE 16 FRANCE DNA VACCINE MARKET 2018-2026 ($ MILLION)
FIGURE 17 GERMANY DNA VACCINE MARKET 2018-2026 ($ MILLION)
FIGURE 18 SPAIN DNA VACCINE MARKET 2018-2026 ($ MILLION)
FIGURE 19 REST OF EUROPE DNA VACCINE MARKET 2018-2026 ($ MILLION)
FIGURE 20 MARKET SHARES OF TOP FIVE COMPANIES FOR DNA VACCINES MARKET IN 2017
- GEOGRAPHICAL ANALYSIS
- EUROPE
- UNITED KINGDOM
- FRANCE
- GERMANY
- SPAIN
- REST OF EUROPE
- EUROPE
- MARKET SEGMENTATION
- MARKET BY TYPE 2018-2026
- ANIMAL DNA VACCINE
- HUMAN DNA VACCINE
- MARKET BY APPLICATION 2018-2026
- HUMAN DISEASE
- VETERINARY DISEASE
- MARKET BY TECHNOLOGY 2018-2026
- PLASMID DNA VACCINES
- PLASMID DNA DELIVERY
- MARKET BY TYPE 2018-2026
To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.